BioMérieux S.A. completed the acquisition of remaining unknown shares in Specific Diagnostics, LLC.
May 18, 2022
Share
bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire remaining unknown shares for €360 million in Specific Diagnostics, LLC on April 12, 2022. Pursuant to the transaction, the purchase price is equivalent to 3.3% of bioMérieux market capitalization as of April 11, 2022 which stood at around EUR 11 billion. The acquisition price will be paid with a combination of cash and shares issued to certain Specific Diagnostics shareholders. The issuance of new bioMérieux shares shall result in a share dilution of approximately 1%. The transaction is subject to customary closing conditions and certain regulatory approvals and is expected to close by the end of Q2 2022. Moelis & Company (NYSE:MC) acted as financial advisor to bioMérieux S.A. in the transaction.
bioMérieux S.A. (ENXTPA:BIM) completed the acquisition of remaining unknown shares in Specific Diagnostics, LLC on May 19, 2022. As a part of this acquisition, bioMérieux now hold 100% stake in Specific Diagnostics.
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
BIOMÉRIEUX 
